Siren L.L.C. Has $42.57 Million Stock Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Siren L.L.C. reduced its position in Centessa Pharmaceuticals by 1.5%, now owning approximately 2,960,029 shares valued at $42.57 million.
• Several hedge funds, including Janus Henderson Group PLC, made significant increases to their positions in Centessa Pharmaceuticals, highlighting strong institutional interest in the company.
• Analysts have a generally positive outlook on Centessa Pharmaceuticals, with an average price target of $28.10 and numerous firms issuing "buy" ratings.

Siren L.L.C. lowered its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 1.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,960,029 shares of the company's stock after selling 44,648 shares during the quarter. Centessa Pharmaceuticals comprises approximately 2.5% of Siren L.L.C.'s holdings, making the stock its 12th largest holding. Siren L.L.C. owned 2.22% of Centessa Pharmaceuticals worth $42,565,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of CNTA. Geode Capital Management LLC increased its position in Centessa Pharmaceuticals by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock worth $959,000 after acquiring an additional 660 shares during the period. Barclays PLC increased its position in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after acquiring an additional 4,952 shares during the period. Voya Investment Management LLC bought a new position in Centessa Pharmaceuticals during the fourth quarter worth $497,000. The Manufacturers Life Insurance Company increased its position in Centessa Pharmaceuticals by 19.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 317,329 shares of the company's stock worth $5,315,000 after acquiring an additional 52,360 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Centessa Pharmaceuticals during the fourth quarter worth $6,117,000. Institutional investors own 82.01% of the company's stock.

Insider Buying and Selling

In related news, insider Mario Alberto Accardi sold 8,322 shares of the business's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $15.23, for a total value of $126,744.06. Following the completion of the transaction, the insider directly owned 208,163 shares in the company, valued at approximately $3,170,322.49. The trade was a 3.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $15.92, for a total value of $875,600.00. Following the completion of the transaction, the chief executive officer owned 221,017 shares of the company's stock, valued at $3,518,590.64. This represents a 19.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 171,322 shares of company stock valued at $2,472,814. Insiders own 7.09% of the company's stock.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA traded down $1.75 on Wednesday, hitting $15.52. 1,196,063 shares of the company were exchanged, compared to its average volume of 961,019. The company has a market cap of $2.08 billion, a P/E ratio of -8.66 and a beta of 1.47. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $9.60 and a 1-year high of $19.09. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average of $15.83 and a two-hundred day moving average of $14.46.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, equities analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on CNTA shares. Chardan Capital reiterated a "buy" rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Tuesday, August 12th. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They issued an "outperform" rating and a $40.00 target price on the stock. Wells Fargo & Company began coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday. They issued an "overweight" rating and a $31.00 target price on the stock. Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They issued a "buy" rating and a $35.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Twelve investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $31.45.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.